NeoGenomics Laboratories competitors

Yvonne Greenstreet is a COO at ALNYLAM PHARMACEUTICALS, INC..

Dr. Brian Alexander was named Chief Executive Officer of Foundation Medicine in March 2021. He previously served as the company’s Chief Medical Officer since 2019, and is a practicing radiation oncologist specializing in neuro-oncology at Dana-Farber/Brigham and Women’s Cancer Center, and a Senior Lecturer at Harvard Medical School. Since joining the company in September 2018 as a Senior Vice President of Clinical Development, Dr. Alexander has played a pivotal leadership role in Foundation Medicine’s decision insights strategy, helping oncologists, both in community and academic settings, determine the right treatment, at the right time, for each unique patient. Under his leadership, Foundation Medicine’s medical team has expanded its molecular tumor board program to include over 90 leading oncology centers globally, launched a cross-functional genomics and health disparities effort, and has developed hundreds of studies and publications to advance the clinical utility of genomic profiling. Dr. Alexander was the founding director of the Program in Regulatory Science at the Dana-Farber Cancer Institute and the Harvard/MIT Center for Regulatory Science. He also co-founded the Global Coalition for Adaptive Research, a non-profit organization focused on clinical trial innovations to accelerate the discovery and development of cures for patients with rare and deadly diseases, and served as chair of the FDA/Project Datasphere task force on external control arms. Dr. Alexander is an affiliated researcher at the MIT Laboratory for Financial Engineering and affiliated faculty of the Harvard Kennedy School Healthcare Policy Program. He was named to Boston Magazine’s “Top Doctors List” in 2019, 2020, and 2021. Previously, Dr. Alexander served as a White House fellow and Special Assistant to the Secretary of Veterans Affairs, where he helped prepare the VA for the transition of administrations, worked to develop a public reporting system for quality, and served as a health policy advisor to the Secretary. Dr. Alexander organized the standup of the VA’s Coordinating Council on National Health Reform and directed the activities of its multi-team Health Reform Working Group. He was also a member of the Institute of Medicine’s Committee on the Governance and Financing of Graduate Medical Education. Dr. Alexander’s research interests focus on innovations in clinical evidence generation to support the development of therapeutics, biomarkers, and novel endpoints. He co-authored a book titled “Diagnostic Test Interpretation and Reasoning Under Uncertainty,” detailing the use of Bayesian approaches to clinical decision-making. Dr. Alexander was the founding principal investigator of INSIGhT, a multi-institutional genomic biomarker-based Bayesian adaptively randomized trial for patients with glioblastoma. He is the recipient of the Burroughs-Wellcome Innovations in Regulatory Science Award for his work applying such approaches to clinical trial design. Dr. Alexander received his B.A. from Kalamazoo College, M.D. from the University of Michigan Medical School, and M.P.H. from the Harvard School of Public Health. He completed his training in radiation oncology at the Harvard Radiation Oncology Program.

Douglas 'Doug' Ingram is a CEO and President at SAREPTA THERAPEUTICS, INC.; Board Member at SAREPTA THERAPEUTICS, INC.; and Board Member at Relay Therapeutics Inc and is based in Irvine, California. He has worked as Assistant General Counsel at Actavis, President at Actavis, and Board Member at Volcom. Douglas works or has worked as BOARD MEMBER at Allergan Foundation and Board Member at Pacific Life. He studied at James E Rogers College of Law until 1988, Arizona State University between 1980 and 1985, and University of Arizona.

Reshma Kewalramani (born 1973), is the president and chief executive officer of Vertex Pharmaceuticals, a biotechnology company based in Boston, Massachusetts, as of April 1, 2020. She is the first female CEO of a large US biotech company. She was previously the chief medical officer and vice president of global medicines development and medical affairs at Vertex.

Skip Wagner is a President and Chief Executive Officer at BioReliance and is based in College Station, Texas.

Joe Owen is a CEO at Guardian Healthcare Providers and is based in Brentwood, Tennessee.

Andrew Walton is a Chief Executive Officer at Miraca Life Sciences and Board Member at OXFORD IMMUNOTEC GLOBAL PLC. He has worked as Senior VP/CIO at LABORATORY CORP OF AMERICA HOLDINGS, Executive In Charge at LABORATORY CORP OF AMERICA HOLDINGS, and Exec VP:Strategic Planning at LABORATORY CORP OF AMERICA HOLDINGS. Andrew attended Yale University and Harvard Business School.

Purpose-driven company and team builder with more than 25 years of life science industry experience including 15+ years as CEO, leading organizations from formation to strategic exit. Proven experience in raising equity and debt capital, and developing strategic plans that result in demonstrable commercial value. Strong track record of negotiating and managing corporate and academic partnerships that drive value-creation, developing effective and aligned executive and operational teams, and recruiting highly-experienced Board of Directors. • “Start to Finish” CEO with experience in all company phases from seed stage to multi-million revenue product commercialization to strategic exit.Responsibility-centered leader who builds cohesive and intellectually aligned executive teams held accountable for collective results. • Proven success in raising multiple rounds of equity and debt capital from venture capital investors, banks, and corporate partners. • Extremely effective in communicating, both internally and externally, the “why” behind an organization’s existence and basis for its success. • Source, negotiate, close, and manage value-creating partnerships with “brand name” academic, pharmaceutical, biotech, and technology companies. • Strong educational foundation and hands-on experience in developing and implementing strategic plans that create value in early and mid-stage stage organizations. • Reputation among board members and employees as a dedicated and inspirational leader with the ability to motivate and maintain teams throughout a company’s lifecycle.• Experience in developing and executing on business models in both rare disease diagnostics and rare disease therapeutics.